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Aim: To identify the localization of glucose-coated gold nanoparticles within cells 
of the brain after intravascular infusion which may point to the mechanism by 
which they cross the blood–brain barrier. Materials & methods: Tissue distribution 
of the nanoparticles was measured by inductively-coupled-mass spectrometry and 
localization within the brain by histochemistry and electron microscopy. Results & 
conclusion: Nanoparticles were identified within neurons and glial cells more than 
10 μm from the nearest microvessel within 10 min of intracarotid infusion. Their 
distribution indicated movement across the endothelial cytosol, and direct transfer 
between cells of the brain. The rapid movement of this class of nanoparticle (<5 nm) 
into the brain demonstrates their potential to carry therapeutic biomolecules or 
imaging reagents.
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Gold nanoparticles have great potential for 
the treatment of brain disorders as they may 
be able to carry therapeutic biomolecules 
across the blood–brain barrier where there 
is normally limited entry. Brain endothelial 
cells possess tight junctions which restrict 
paracellular movement of small molecules, 
proteins and nucleic acids. Moreover, many 
xenobiotics including cytotoxic drugs and 
antibiotics, are actively removed by multi-
drug transporters present on the endothe-
lium [1]. Gold nanoparticles (5–80 nm) 
are able to penetrate the brain paren-
chyma [2–6], and could therefore be used 
to carry a therapeutic agent into the brain. 
However, little is known about the detailed 
ultrastructural fate of the nanoparticles in 
the brain. It is vital to gain understanding 
on which cell types they target in order to 
develop a functional brain therapy, while 
reducing possible adverse effects on other 
cell types.
Glyconanotechnology is a new field of 
nanotechnology, promising to enhance 
understanding of glycans and their interac-
tions with cells as well as the use of glycan-
coated nanomaterials in nanomedicine [7]. 
Glycan-coated gold nanoparticles have been 
used to prevent cell–cell adhesion or inter-
action between cells and pathogens and in 
diagnostics [8]. They are also emerging as 
nanomaterials for drug delivery [9]. In our 
previous study, we have found that gold 
nanoparticles with glucose coating (<5 nm) 
are able to enter and cross human brain 
endothelium in vitro [10], implying that they 
could be used for delivery of brain therapies 
such as siRNA, cytokines and small drugs. 
However, these different therapeutic agents 
have distinct target zones within the brain. 
For example, cytokines act within the extra-
cellular space, whereas siRNA must reach 
the cytosol of the correct target cell type. 
Therefore, it is essential to determine exactly 
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Figure 1. Determination of blood–brain barrier integrity by immunohistochemistry. Immunoglobulins were 
stained (blue) in coronal sections. Staining appeared in poorly perfused blood vessels (full arrows). Slight leakage 
of the immunoglobulin (outlined arrows) was observed in both hemispheres of the brain indicating that the 
leakage itself could not be caused by the injection procedure. Scale bars on the left 500 μm, on the right 100 μm. 
Representative images are shown.
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where nanocarriers localize at the ultrastructural level. 
This study demonstrates that gold nanoparticles can 
cross the blood–brain barrier in vivo and move rapidly 
through the brain parenchyma. Transmission electron 
microscopy revealed details of the subcellular distribu-
tion of the nanoparticles within different cell types of 
the brain and elucidated the possible transport mecha-
nisms across the blood–brain barrier and through the 
brain.
Materials & methods
Full details of all the methods are given in the 
Supplementary Material.
Synthesis & characterization of glucose-coated 
gold nanoparticles
Gold nanoparticles with covalently bound glucose on a 
2-carbon spacer were prepared in a single step modifi-
cation of the Brust–Schiffrin method [11]. Coating with 
ligands was achieved during the reduction of HAuCl
4
. 
Thioethyl β-D-glucopyranoside was added into the 
reaction mixture with HAuCl
4
 in methanol before 
reduction with NaBH
4
. The resulting nanoparticles 
were <5 nm in diameter with a 2-nm gold core.
Animals & nanoparticle administration
The experimental protocols used in this study 
were approved by the Local Ethics Committee 
for Animal Experimentation of Istanbul Univer-
sity (2014/06). Detailed protocols are given in the 
Supplementary Material. Briefly, the nanoparti-
cles (50 μg Au in 100 μl) were injected into the left 
carotid artery of anesthetized adult male Wistar rats 
(250–300 g, n = 4) over the course of 2 min using an 
infusion pump. The nanoparticles circulated for 10 min 
before the animals were transcardially perfused with 75 
ml 0.9% saline, followed by fixation with 200 ml of fix-
ative containing 2.5% glutaraldehyde and 2% parafor-
maldehyde in 0.1 M PB (phosphate buffer) for 15 min. 
Brain, liver, lung and kidney were taken for analysis.
Analysis of gold content in brain, liver, kidney 
& lung
Tissue samples were digested in boiling HNO
3
 before 
analysis by ICP-MS (inductively-coupled mass spec-
trometry) to quantify gold. The results were first 
expressed as [μg gold/mg tissue] and the values were 
then compensated to account for variation in the 
weights of the animals.
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Figure 2. Analysis of gold content in tissues 10 min 
after intracarotid injection. The values are mean 
± standard error of the mean from four animals, 
initially calculated as μg gold/mg of tissue and then 
compensated for variation in the initial concentration 
of the nanoparticles according to the weight of each 
animal, here shown as relative amount to the animal 
weight. The difference between ipsilateral and 
contralateral side was ns (paired t-test). 
ns: Not significant.
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Immunohistochemistry & electron microscopy
Fixed brains were initially sectioned (100 μm) with 
a vibratome and a coronal section corresponding to 
the start of the hippocampus in each animal was ana-
lyzed. Then they were permeabilized (0.01% Triton-
X100) and enhanced by silver enhancement in order 
to increase the size of nanoparticles to approximately 
20 nm, which also produced brown staining cor-
responding to the areas containing high levels of 
nanoparticles. The 100 μm sections were imaged by 
light microscopy. The sections were then stained with 
1% osmium tetroxide to increase contrast and further 
processed for electron microscopy. Ultrathin sections 
(80 nm) were counter-stained with uranyl acetate and 
lead citrate and imaged by a transmission electron 
microscope, JEOL 1010, at 80 kV.
To check that blood–brain barrier integrity had not 
been compromised by the nanoparticle infusion, par-
allel sections to those imaged by electron microscopy 
were stained for the presence of rat immunoglobulin 
to determine whether any protein leakage from the 
microvessels had occurred (Note that the molecular 
diameter of IgG, ∼5.5 nm, is similar to the nanopar-
ticles). The density of the blood vessels in rat cortex 
was measured on the electron microscope, using imag-
ing software AmtV 600, to determine the distance to 
the nearest microvessel.
Results
Previous studies have shown that gold nanoparticles 
can enter the brain following intravenous [2–3,12] or 
intraperitoneal [5] injection. In this study, we injected 
50 μg of glucose-coated gold nanoparticles into the 
left carotid artery. This protocol allowed for a high 
local concentration of gold nanoparticles in the left 
hemisphere of the brain (ipsilateral side) while keep-
ing the blood–brain barrier undisturbed (Figure 1). 
Nanoparticles that exited the cerebral circulation 
after passing through the ipsilateral side of the brain 
then passed through the pulmonary circulation. 
They then distributed via the systemic circulation 
into other organs, including the liver, kidney and 
right side of the brain (contralateral side). Analysis 
of the distribution of gold in the different tissues by 
ICP-MS (Figure 2) showed highest concentrations of 
nanoparticles in the kidney, which is characteristic of 
nanoparticles of this size [13]. The nanoparticles were 
also detected in the brain; the levels in the ipsilateral 
side were similar to the levels in the lung and liver. 
Moreover, the level of accumulation was approxi-
mately three-times higher in the ipsilateral side than 
in the contralateral side of the brain, although the 
difference was not statistically significant (one-way 
paired t-test, p = 0.09).
The cellular localization of the nanoparticles in the 
brain was determined by transmission electron micros-
copy. Silver enhancement of gold present in coronal 
sections identified areas of the cortex with the highest 
levels of gold (Figure 3A). Note that the silver enhance-
ment is not directly proportional to the amount of 
gold present – gold was also detected in areas of the 
contralateral cortex by ICP-MS and electron micros-
copy, albeit at lower levels than in the stained areas. 
Silver-enhanced nanoparticles were observed in the 
cytosol of endothelial cells (Figure 3B), but not in tight 
junctions between the endothelial cells or in their 
vesicles. We also confirmed that the silver enhance-
ment does not cause nonspecific staining, by silver-
enhancing a brain section of an uninjected animal 
(Supplementary Figure 1).
Beyond the brain endothelium, the nanoparticles 
were observed at the basal lamina and in pericytes 
(Supplementary Figure 2). In brain parenchyma, 
the nanoparticles were detected in the cytosol and 
nucleus of glial cells (Supplementary Figure 3) as well 
as in neurons, both in the cell bodies and in axons 
of myelinated and unmyelinated neurons (Figure 4 
& Supplementary Figure 4). A very small number of 
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Figure 3. Glucose-coated gold nanoparticles in rat brain. (A) Silver-stained coronal section; the rectangle 
corresponds to the area of cortex examined by electron microscopy. (B) Gold nanoparticle (arrow) in the cytosol of 
an endothelial cell (ii). (Bi) Blood vessel lumen. Scale bar: 1 μm.
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nanoparticles were seen in the extracellular spaces 
(Figure 4).
We also analyzed the distance that these nanopar-
ticles were observed from the blood vessel in the brain 
parenchyma. Within the 10 min time-frame of the 
experiment, many nanoparticles have been observed 
more than 10 μm from the nearest visible capillary 
(Figure 5 & Supplementary Figure 5).
Discussion
This study demonstrated that glucose-coated gold 
nanoparticles (<5 nm) can enter the brain of rats 10 
min after intracarotid injection. At the cellular level, 
the nanoparticles localized in the cytosol of brain 
endothelium and were able to enter glial cells and 
neurons in the cortex. Nanoparticles had moved more 
than 10 μm from the nearest visible capillary.
The intracarotid administration used in this study is 
regularly employed to enhance uptake of substances by 
the brain. For example, it is common in applications of 
substances to open the blood–brain barrier with man-
nitol or TNF-α [14,15] as well as in a clinical setting to 
help to treat neurological conditions such as ischemic 
stroke or intracranial malignancies [16]. Intracarotid 
injection has not been used previously to administer 
nanoparticles to animals, possibly because of the nec-
essary surgical expertise required. We showed that this 
route can be useful to study nanoparticle migration 
into the brain, with the advantage of having a two-
in-one picture: one hemisphere was directly affected 
by the bolus injection whereas the second hemisphere 
functioned as a control, where the nanoparticle local-
ization would be similar to a more classical route, such 
as intravenous injection via the tail vein.
The tissue distribution showed that most of the 
nanoparticles were detected in the kidney, an organ 
which has fenestrated endothelium. This finding 
agrees with previously published work, which has 
shown that smaller nanoparticles (<8 nm) localize in 
kidney, whereas larger ones (>10 nm) are often taken 
up by mononuclear phagocytes, particularly in the 
liver and spleen [13].
At the end of the 10 min infusion, the amount of 
gold in the blood was approximately 1 μg/ml, while 
the mean amount in the ipsilateral side of brain was 
15 ng/g tissue as measured by ICP-MS. This amount 
(∼1.5% of the blood concentration) may appear low; 
however, it is high in comparison with the expected 
level of transport of a molecule of this size. It is pos-
sible to assess brain penetration of a molecule by com-
paring the levels in the cerebrospinal fluid with the 
levels present in serum (CSF:serum ratio). In this 
case, hydrophilic molecules of 5 nm, which are not 
actively transported (e.g., IgG), are present in cere-
brospinal fluid at approximately 0.2% of the serum 
concentration (CSF:serum ratio = 0.002) [17]. Even 
ligands designed to improve drug delivery across the 
blood–brain barrier only demonstrate brain penetra-
tion between 0.2 and 3% (e.g., monoclonal antibod-
ies to transferrin receptor, or insulin receptor at 3 h 
after infusion) [18]. The level of entry of these gold 
nanoparticles into cortex is therefore remarkably 
high, particularly given the short time-frame of the 
experiments.
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Figure 4. Glucose-coated gold nanoparticles in brain parenchyma. Nanoparticles localized in myelinated axons 
(B & C), unmyelinated axons/dendrites (A & D) and in the extracellular space (E). Scale bar: 1 μm.
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It is essential to distinguish nanoparticles present 
in the brain parenchyma from any present within the 
brain vasculature. In our experiments the animals were 
perfused to clear the vasculature from blood after the 
injection, and the difference between the levels in the 
injected and noninjected sides (as detected by ICP-MS) 
implies that the nanoparticles are not located in resid-
ual blood within cerebral vessels. This is confirmed by 
TEM images which show perfused blood vessels and 
nanoparticles in endothelium, neurons and glia. The 
nanoparticle distribution in the brain varied depending 
on what part of the brain was analyzed; cerebellum had 
lower levels in comparison with the contralateral side 
of the brain (Figure 2). The differences may partly be 
explained by different levels of vascularization of these 
areas of the brain. More surprising was the observation 
that the silver-enhanced coronal sections (Figure 3A) 
indicated local variation in the levels of nanoparticles in 
different areas of the ipsilateral side of the brain. We con-
sidered the possibility that the injection itself might have 
disrupted the barrier in some areas. However, immuno-
histochemistry revealed comparable blood vessel integ-
rity in ipsilateral and contralateral sides of the brain 
(Figure 1) and electron micrographs showed no evidence 
of barrier disruption or endothelial damage (Figures 3 
& 5 & Supplementary Figure 5). Another explanation for 
this variation may be intravascular streaming that fol-
lows infusion into the carotid artery [19]. Intravascular 
streaming causes variability in drug distribution in the 
brain and can lead to local toxicity [19,20]. It is the most 
likely explanation for the uneven distribution of gold 
nanoparticles that we have observed in the cortex.
We observed the glucose-coated gold nanoparticles 
in the cytosol of the brain endothelium, suggesting 
that they can enter the brain endothelium by passive 
transport. This observation is in accordance with our 
study in vitro [10], which suggested that glucose-coated 
nanoparticles primarily moved across human brain 
endothelium through the cytosol, crossing the apical 
and basal plasma membranes. There are several mod-
els of this passive transport mechanism that have tried 
to explain this phenomenon [21–23]. It is possible that 
the initial interaction of the nanoparticles with the 
cell membrane may also be affected by the endothelial 
glycocalyx and membrane proteins. In our previous 
study [10] we found that the endothelial Glut-1 trans-
porter is not involved in the uptake of nanoparticles as 
inhibition of the transporter did not affect nanoparti-
cle transmigration. The glucose is attached to a carbon 
linker which extends from the nanoparticle in a way 
that makes it unrecognizable to the transporter [11,24]. 
Therefore, the function of glucose is to stabilize the 
622 Nanomedicine (Lond.) (2016) 11(6)
Figure 5. Distance traveled by glucose-coated gold nanoparticles in cortex. The nanoparticles (arrows) located at 
various distance (dashed line) from the blood vessel (v); examples: (A) 5 μm, (B) 7 μm. Scale bar: 2 μm.
v
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nanoparticle and provide it with neutral charge (more 
details on characterization of the nanoparticles are 
given in the Supplementary Material).
Larger gold nanoparticles (80 and 13 nm) have been 
shown to enter cerebral cortex by electron micros-
copy [5,6], however, detailed ultrastructural analysis 
especially for small nanoparticles, has not been done 
previously. Our glucose-coated gold nanoparticles 
entered neurons and glial cells of the cortex (Figure 6 
& Supplementary Figure 3). In comparison with the 
published studies [5,6], the nanoparticles were able to 
enter the nucleus as well as the cytosol of the cells 
which may be inherent to their size, but further stud-
ies in vitro would be necessary to uncover the mecha-
nism of nuclear transport. The route the nanopar-
ticles may take into the nucleus would involve either 
crossing the double nuclear membrane or moving 
through the nuclear pore. The nuclear pore com-
plex (size about 120 nm) allows passive diffusion of 
molecules of up to 40 kDa [25] and our nanoparti-
cles (mean molecular mass of 27 kDa) would fit this 
criterion. Nuclear localization of nanoparticles also 
suggests a potential use for radiotherapy or a nuclear 
gene therapy.
The distance that the nanoparticles had moved 
in the brain was over 10 μm. This corresponds with 
the high rate of movement that we observed previ-
ously in vitro [10]. It implies that the tightly-packed 
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Figure 6. Gold nanoparticles in a neuronal cell body. (A) Nanoparticles (arrows) located in the cytosol (Aii & Bii) of 
a neuronal cell. The rectangular inset is enlarged (B). (Ai & Bi) nucleus of a neuron, (Aiii & Biii) brain parenchyma. 
Scale bar: 1 μm.
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cells of the brain cortex do not present a substantial 
barrier to these nanoparticles. The nanoparticles 
were located in high numbers intracellularly in com-
parison with extracellular spaces, which suggested 
direct movement between cells. The distance the 
nanoparticles traveled implies that they are not mov-
ing by diffusion in the tortuous extracellular spaces. 
It is estimated that all cells of the brain are within 
50 μm of a capillary [26]. This distance corresponds 
with the density of vessels that we observed in the 
electron micrographs, where the mean distance of 
blood vessels in the 2D space of the sections was mea-
sured as 50.6 ± 25.5 μm, based on 106 measurements 
(Supplementary Figures 6 & 7). Could the nanopar-
ticles (Figure 5 & Supplementary Figure 5) have moved 
to their position from a microvessel that is not seen in 
the images? This would require a much higher den-
sity of microvessels in the cortex than is observed here 
or reported previously [26]. Each section viewed on the 
electron microscope is 80 nm thick. Assuming that 
the rates of movement demonstrated in vivo are cor-
rect, it implies that nanoparticles of this type could 
permeate all areas of the cortex within 50 min. The 
movement of the nanoparticles through the brain 
parenchyma might be facilitated by the perivascu-
lar spaces, between endothelium and astrocyte foot 
process, or the ‘glymphatic system’ [27], which may 
be responsible for removing molecules from the brain 
such as amyloid-β [28]. However, the nanoparticles 
were not specifically observed in these areas.
This study points out the potential of glucose-coated 
gold nanoparticles for carrying a therapeutic substance 
into the brain cortex. Due to their large surface area 
that can hold up to 40 covalently bound ligands, the 
amount that they may be able to deliver might be ther-
apeutically useful. In comparison to free drug mol-
ecules, the nanoparticles may also improve the drug 
efficiency by providing a depot for small drug release, 
or by orientating clusters of biomolecule ligands to act 
on cell surface receptors.
Conclusion
Nanoparticle-based therapeutic delivery into the cortex 
may be relevant to delivery of treatment for neurologi-
cal conditions. Also, knowledge of nanocarrier behav-
ior is crucial for improving the design of nanoparticles 
for targeting cells of the brain and optimizing trans-
port and release of a potential cargo. Future stud-
ies with more time points would reveal the time and 
speed with which the nanoparticles are cleared from 
the brain. To conclude, we believe that the type of 
investigation shown here is essential for the develop-
ment of any nanoparticle-based therapy, including the 
use of nanoparticles as drug carriers, therapeutic agents 
themselves or for imaging.
Future perspective
The major developments in disease treatments for the 
last 10 years have been in biological agents, all of which 
are excluded from the brain by the blood–brain barrier. 
There are several promising approaches for treatment 
of neurological conditions, including use of siRNA and 
cytokines; the challenge for researchers is to develop a 
way of transporting these agents into the brain.
First, a suitable carrier needs to be developed (as 
demonstrated in this paper), then it must be loaded 
with a biomolecule, that does not affect the transport 
properties across brain endothelium. Once the carrier 
has entered the brain it should release its therapeutic 
cargo and then be cleared, either by transcytosis/dif-
624 Nanomedicine (Lond.) (2016) 11(6) future science group
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fusion/excretion or by biological breakdown. Over the 
next decade, we believe that the combined chemical 
and biological problems will be solved, so that imaging 
agents and therapeutic molecules can be delivered into 
the brain. Nanomedicine presents the most promising 
way forward in this area.
Supplementary data
To view the supplementary data that accompany this paper, 
please visit the journal website at: www.futuremedicine.com/
doi/full/10.2217/NNM.15.215
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Executive summary
•	 Glucose-coated gold nanoparticles (<5 nm) entered the brain within 10-min of intracarotid injection.
•	 The nanoparticle concentration within the brain is comparable to that in liver and lung, but much lower than 
in the kidney.
•	 Within the brain cortex, the nanoparticles were observed in cytosol of endothelial cells, implying a possible 
passive transport across the brain endothelium.
•	 In the cortical parenchyma, the nanoparticles localized within the cytosol and nucleus of both neurons and 
glial cells, pointing to their potential use for delivery of therapeutic agents as well as use for radiotherapy.
•	 The nanoparticles were observed more than 10 μm from the nearest capillary, suggesting that they may be 
able to move at more than 1 μm per minute within the cortex.
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